ACE Research: Established in 2014 as a private company limited by shares in the Republic of Kenya (Reg. CPR/2014/168983), ACE Research is a leading African niche full-service CRO specializing in early and late-phase clinical research on infectious diseases, emerging pathogens, and bio-threats. The company is registered in Kenya (East Africa), Sierra Leone (West Africa), and the Democratic Republic of Congo (Central Africa). With a total headcount of 60, ACE Research is well-equipped with offices and scientific, medical, and clinical operation experts to deliver Track A responsibilities, including clinical site feasibility gap analysis, shortlisting of clinical sites, capacity development planning, and strategy documentation. The company has a geographic footprint and rich past performance in 37 African countries in Sub-Saharan Africa. Notable relevant outbreak and pandemic response experiences of WHO and Africa CDC list of pathogen clinical trials include Lassa fever in Liberia (NCT04794218), COVID-19 in Kenya, DRC, Rwanda, Uganda (NCT05209009, PACTR202203582920839, WHO), Ebola Virus disease (EVD) in Sierra Leone, Liberia, DRC, Uganda Ivory Coast, Nigeria Kenya, Mozambique, Guinea and Burkina Faso (NCT04152486, NCT04186000, NCT05064956, NCT02661464, NCT02509494, NCT02876328, ISRCTN15779782), WHO Solidarity COVID-19 Trials, among other outbreak response research programs. In addition, ACE, UNIKIN, and Bavarian Nordic are collaborating on CEPI-funded Mpox vaccine trials in children aged 2-12 years in the DRC and Uganda. ACE Research is a trusted partner of various industry, academic, and non-profit organizations, including the WHO, CEPI, Janssen Vaccines & Prevention B.V., Mapp Biopharmaceutical, Roche, NuVox Pharma, Hemex Health, IQVIA, ICON Plc, KAI Research, TCD, C3 Associates Research, Henry M. Jackson Foundation for the Advancement of Military Medicine, London School of Hygiene & Tropical Medicine, University of Antwerp, DNDi, PATH, IAVI, FIND Diagnostics, among other organizations.